Treating renal cell carcinoma in young adults: challenges and solutions

References

• Spreafico F, Collini P, Terenziani M, Marchianò A, Piva L. Renal cell carcinoma in children and adolescents. Expert Rev Anticancer Ther. 2010;10(12):1967–1978.
   Web of Science ®Google Scholar
• Suh JH, Oak T, Ro JY, Truong LD, Ayala AG, Shen SS. Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell darcinoma in older patients. Int J Clin Exp Pathol. 2009;2(5):489–493.
   Web of Science ®Google Scholar
• Rodríguez A, Patard JJ, Lobel B. Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. Arch Esp Urol. 2002;55(8):969–975.
   Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–1132.
   PubMed Web of Science ®Google Scholar
• Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7(6):327–338.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009;103(5):572–577.
   Web of Science ®Google Scholar
• Soulières D. Review of guidelines on the treatment of metastatic renal cell carcinoma. Curr Oncol. 2009;16(suppl 1):S67–S70.
   Google Scholar
• Escudier B, Kataja V, ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v137–v139.
   PubMedGoogle Scholar
• Pace K. Determining the best treatment for renal cell carcinoma in young patients. Can Urol Assoc J. 2008;2(6):618.
   Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966.
   PubMed Web of Science ®Google Scholar
• Su HH, Sung MT, Chiang PH, Cheng YT, Chen YT. The preliminary experiences of translocation renal cell carcinoma and literature review. Kaohsiung J Med Sci. 2014;30(8):402–408.
   PubMed Web of Science ®Google Scholar
• Xu L, Yang R, Gan W, et al. Xp11.2 translocation renal cell carcinomas in young adults. BMC Urol. 2015;15(1):57.
   Google Scholar
• Selle B, Furtwängler R, Graf N, Kaatsch P, Bruder E, Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer. 2006;107(12):2906–2914.
   Web of Science ®Google Scholar
• Argani P, Ladanyi M. Recent advances in pediatric renal neoplasia. Adv Anat Pathol. 2003;10(5):243–260.
   Web of Science ®Google Scholar
• Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369–373.
   PubMed Web of Science ®Google Scholar
• Argani P, Laé M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24(10):1529–1534.
   Web of Science ®Google Scholar
• Schafernak KT, Yang XJ, Hsueh W, Leestma JL, Stagl J, Goldman S. Pediatric renal cell carcinoma as second malignancy: reports of two cases and review of the literature. Can J Urol. 2007;14(6):3739–3744.
   Google Scholar
• de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet. 1986;21(2):165–169.
   PubMedGoogle Scholar
• Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 2014;27(6):875–876.
   PubMed Web of Science ®Google Scholar
• Malouf GG, Monzon FA, Couturier J, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res. 2013;19(17):4673–4684.
   Web of Science ®Google Scholar
• Magers MJ, Udager AM, Mehra R. MiT family translocation-associated renal cell carcinoma: a contemporary update with emphasis on morphologic, immunophenotypic, and molecular mimics. Arch Pathol Lab Med. 2015;139(10):1224–1233.
   Web of Science ®Google Scholar
• Numakura K, Tsuchiya N, Yuasa T, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16(5):577–580.
   Web of Science ®Google Scholar
• Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009;7(3):E93–E94.
   PubMed Web of Science ®Google Scholar
• Gorin MA, Ball MW, Pierorazio PM, Argani P, Allaf ME. Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):e199–e201.
   Web of Science ®Google Scholar
• Zhao RR, Nie LH, Gong R, et al. Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature. Int Urol Nephrol. 2013;45(4):1017–1021.
   Web of Science ®Google Scholar
• Bejar J, Szvalb S, Maly B, Munichor M, Cohen H. Collecting duct carcinoma of kidney: a cytological study and case report. Diagn Cytopathol. 1996;15(2):136–138.
   Web of Science ®Google Scholar
• Gupta R, Billis A, Shah RB, et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol. 2012;36(9):1265–1278.
   Web of Science ®Google Scholar
• Xu Q, Cao Q, Liu N, Fang Z, Ye Z, Peng T. Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review. Diagn Pathol. 2013;8:119.
   Web of Science ®Google Scholar
• Amin MB, Varma MD, Tickoo SK, Ro JY. Collecting duct carcinoma of the kidney. Adv Anat Pathol. 1997;4:85–94.
   Google Scholar
• Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998;15(1):54–67.
   Web of Science ®Google Scholar
• Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
   Google Scholar
• Amin MB, Smith SC, Agaimy A, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38(7):871–874.
   Web of Science ®Google Scholar
• Amjad AI, Ali H, Appleman LJ, et al. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Case Rep Oncol Med. 2014;2014:615895.
   Google Scholar
• Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11.
   Web of Science ®Google Scholar
• Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 2002;60(6):1083–1089.
   Web of Science ®Google Scholar
• Watanabe IC, Billis A, Guimarães MS, et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol. 2007;20(9):914–920.
   Web of Science ®Google Scholar
• Coogan CL, McKiel CF Jr, Flanagan MJ, Bormes TP, Matkov TG. Renal medullary carcinoma in patients with sickle cell trait. Urology. 1998;51(6):1049–1050.
   Web of Science ®Google Scholar
• Noguera-Irizarry WG, Hibshoosh H, Papadopoulos KP. Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol. 2003;26(5):489–492.
   Web of Science ®Google Scholar
• Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology. 2007;70(5):878–882.
   Web of Science ®Google Scholar
• Daher P, Bourgi A, Riachy E, Khoury A, Rehayem C, Sader-Ghorra C. Renal medullary carcinoma in a white adolescent with sickle cell trait. J Pediatr Hematol Oncol. 2014;36(5):e285–e289.
   Google Scholar
• Gatalica Z, Lilleberg SL, Monzon FA, et al. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42(12):1979–1988.
   Web of Science ®Google Scholar
• Stahlschmidt J, Cullinane C, Roberts P, Picton SV. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol. 1999;33(6):551–557.
   Google Scholar
• Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61(3):428–435.
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106(1):62–65.
   Web of Science ®Google Scholar
• Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer. 2004;100(5):976–985.
   Web of Science ®Google Scholar
• Walsh A, Kelly DR, Vaid YN, Hilliard LM, Friedman GK. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2010;55(6):1217–1220.
   Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006;24(9):e14.
   Google Scholar
• Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22(18):3720–3725.
   PubMed Web of Science ®Google Scholar
• Al-Rahawan MM, Rapkin L, Smith SD. Active combination of platins/ paclitaxel/gemcitabine/bortezomib in a child with metastatic renal medullary carcinoma (RMC). J Clin Oncol. 2011;29(15 suppl):e20002.
   Web of Science ®Google Scholar
• Lipkin JS, Rizvi SM, Gatalica Z, et al. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther. 2015;16(1):28–33.
   PubMed Web of Science ®Google Scholar
• Rowe RG, Thomas DG, Schuetze SM, Hafez KS, Lawlor ER, Chugh R. Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors. Urology. 2013;81(2):347–353.
   Web of Science ®Google Scholar
• Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer. 2007;110(2):375–384.
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol. 2006;45(4):469–475.
   PubMed Web of Science ®Google Scholar
• Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol. 1993;21(3):172–181.
   PubMedGoogle Scholar
• Cotton CA, Peterson S, Norkool PA, et al. Early and late mortality after diagnosis of Wilms tumor. J Clin Oncol. 2009;27:1304–1309.
   Web of Science ®Google Scholar